1. Refer to word document for this table
Supplementary Table 1: AEs amongst all patients treated on trial
Refer to word document for this table

2. Seroreactivity (any timepoint) - Endpoint ELISA
Supplemental Table 2: Number of patients in each cohort with any seroreactivity against the candidate antigens (HPV 16,18 E6 and E7) at (A) any timepoint following vaccination and (B) three months following final vaccination A
 Seroreactivity (any timepoint) - Endpoint ELISA
Cohort 1
Cohort 2
All Patients
HPV16 E6
3/5 (60.0%)
6/12 (50.0%)
9/17 (52.9%)
HPV16 E7
8/12(66.7%)
11/17 (64.7%)
HPV18 E6
1/5 (20.0%)
7/12 (58.3%)
8/17 (47.1%)
HPV18 E7
5/5 (100%)
10/12 (83.3%)
15/17 (88.2%)
Any Antigen
12/12 (100%)
17/17 (100%) B
 Seroreactivity (three months following final vaccination) - Endpoint ELISA
Cohort 1
Cohort 2
All Patients
HPV16 E6
1/4 (25.0%)
1/8 (12.5%)
2/12 (16.7%)
HPV16 E7
2/4 (50.0%)
3/8 (37.5%)
5/12 (41.6%)
HPV18 E6
2/8 (25.0%)
3/12 (25.0%)
HPV18 E7
4/4 (100%)
5/8 (62.5%)
9/12 (75.0%)
Any antigen

3. HPV16 Specific CD8+ T cells expressing activation markers
and lytic proteins (% of total CD3+CD8+)
Patient ID
Flow Cytometry Output
Pre MEDI0457
Post MEDI0457
Difference 01
CD137+GrzA+GrzB+Prf+
0.0%
CD69+GrzA+GrzB+Prf+
CD38+GrzA+GrzB+Prf+ 02
0.33%
0.68%
0.57% 03
0.17%
-0.17%
0.30%
-0.30% 05
0.24%
0.21%
-0.21% 09
0.18%
-0.18%
0.28%
1.12% 10
0.07%
0.52%
0.45%
1.16%
1.38% 11 13
0.08%
-0.08%
0.86%
0.89%
0.03%
0.34%
0.50%
0.16%
Supplemental Table 3: Flow cytometry output frequencies for HPV16 specific CD8+ T cells before and after treatment with MEDI0457

4. HPV18 Specific CD8+ T cells expressing activation markers
and lytic proteins (% of total CD3+CD8+)
Patient ID
Flow Cytometry Output
Pre MEDI0457
Post MEDI0457
Difference 01
CD137+GrzA+GrzB+Prf+
0.11%
0.0%
-0.11%
CD69+GrzA+GrzB+Prf+
0.32%
-0.32%
CD38+GrzA+GrzB+Prf+ 02
0.04%
0.14% 03
-0.04% 05
0.17%
0.35%
0.18%
0.34%
0.06%
-0.28% 09
0.40%
1.33% 10
0.05%
0.24%
0.19%
0.83%
1.11% 11
0.29%
-0.29% 13
0.07%
1.21%
1.03%
Supplemental Table 4: Flow cytometry output frequencies for HPV18 specific CD8+ T cells before and after treatment with MEDI0457

5. Supplementary Figure S1A: Flow Cytometry Gating for assessment of CD3+ CD8+ cells
SSC
Dump Channel
CD8
FSC
CD3
CD3

6. Before Activation (Negative After Activation (Positive
Supplementary Figure S1B: Differential expression of CD38, CD69 and CD137 on CD3+ CD8+ cells before and after activation
Before Activation (Negative
Control)
After Activation (Positive
Control)
CD38
CD69
CD137